← Back to feed

Genflow Biosciences

GENF · Main Market · Health Care · mcap £12m today

All announcements

All RNS · 35 Key events · 29

05 Oct 26

Presentation of Interim Results

Presentation of Interim Results from SLAB Canine Study at the Animal Longevity Summit
RNS 9805359 ↗
29 Sep 26

Exercise of Warrants and Issue of Equity

Genflow (LSE: GENF) (OTCQB: GENFF) ("Genflow" or the "Company"), a biotechnology company focused on the development of gene therapies for age-related diseases announces that it has received notices of exercise of warrants for a total of 28,124,999 new...
RNS 9796936 ↗
29 Sep 26

Half-year Results

Genflow (LSE: GENF) (OTCQB:GENFF) is pleased to announce its half year results for the six-month period ended 30 June 2022.
RNS 9795243 ↗
08 Sep 26

Primary Endpoint in SLAB Clinical Trial Met

Genflow Meets Primary Endpoint in SLAB Clinical Trial
RNS 9759932 ↗
07 Sep 26

Appointment of Investor Relations Adviser

Genflow Appoints ON365 Partners as Investor Relations Adviser
RNS 9757614 ↗
03 Aug 26

Patent Update

Genflow Biosciences Plc (LSE:GENF) (OTCQB:GENFF) ("Genflow" or the "Company"), an emerging leader in the field of longevity research, announces progress across its two principal SIRT6 patent families covering its centenarian-derived SIRT6 variant (SIRT6c;...
RNS 9699670 ↗
13 Jul 26

Mid-Year Operational and Corporate Summary

Genflow Biosciences Plc (LSE:GENF) (OTCQB:GENFF) ("Genflow" or the "Company"), an emerging leader in the field of longevity research, provides a mid-year operational and corporate summary covering the six-month period to 30 June 2026.
RNS 9664252 ↗
29 Jun 26

Result of AGM
RNS 9642155 ↗
22 Jun 26

Participation at BIO International Convention 2026

Genflow Announces Participation at BIO International Convention 2026
RNS 9628768 ↗
17 Jun 26

Company to present at Animal Longevity Summit 2026

Genflow Biosciences to Present SLAB Trial Results at Animal Longevity Summit 2026
RNS 9621962 ↗
04 Jun 26

Notice of AGM
RNS 9600711 ↗
08 May 26

Exercise of Warrants and Issue of Equity

Genflow (LSE: GENF) (OTCQB: GENFF) ("Genflow" or the "Company"), a biotechnology company focused on the development of gene therapies for age-related diseases announces that it has received notices of exercise of warrants for a total of 30,756,577 new...
RNS 9559497 ↗
30 Apr 26

Final Results

Genflow Biosciences Plc (LSE:GENF) (OTCQB:GENFF) ("Genflow" or "the Company"), an emerging leader in the field of longevity research, focused on developing therapeutic solutions for the prevention of age-related diseases, is pleased to announce its final...
RNS 9547223 ↗
28 Apr 26

Expansion of Confidentiality Agreements

Expansion of Confidentiality Agreements with Tier-1 Animal Health Companies
RNS 9540485 ↗
20 Apr 26

Strategic Technology Collaboration

Genflow Biosciences Enters Strategic Technology Collaboration with Acuitas Therapeutics - Fully Funded, Non-Dilutive Access to World-Class LNP Delivery Platform
RNS 9527027 ↗
13 Apr 26

International Patent Publication

International Patent Publication Expands Protection for SIRT6-Based Muscular Disease Program
RNS 9515842 ↗
08 Apr 26

Update on the Dog Study

Genflow Reports Sustained Safety and Efficacy Three Months Post Dosing in SLAB Trial
RNS 9510190 ↗
31 Mar 26

Total Voting Rights
RNS 9499061 ↗
05 Mar 26

Issue of Equity & PDMR Notifications Director buys

Successful Subscription to Raise £800,000 and PDMR Notifications
RNS 9460451 ↗
02 Mar 26

Result of General Meeting

Genflow Biosciences Plc (LSE:GENF) (OTCQB:GENFF) ("Genflow" or "the Company") a leading European-based biotechnology company focusing on longevity, is pleased to announce that all resolutions proposed at the General Meeting held earlier today were duly...
RNS 9453923 ↗
02 Mar 26

Receipt of First Tranche of Grant

Receipt of First Tranche of €4 Million Non-Dilutive Funding from Wallonia Region for GF-1002 Development
RNS 9452340 ↗
12 Feb 26

Preliminary Interim Results From Dog Study

Positive Preliminary Interim Results from SLAB Clinical Trial of SIRT6 Gene Therapy in Aged Dogs
RNS 9426994 ↗
11 Feb 26

Notice of GM

Genflow Biosciences Plc (LSE: GENF) (OTCQB: GENFF) ("Genflow" or the "Company"), a European-based biotechnology company focused on the development of gene therapies for age-related diseases, announces that the Board is considering potentially undertaking...
RNS 9424833 ↗
30 Jan 26

Holding(s) in Company
RNS 9396416 ↗
28 Jan 26

Administrative Approval of Grant & 2026 Priorities

Administrative Approval of €4 Million Funding Support from Wallonia Region for GF-100; and 2026 Development Priorities
RNS 9390352 ↗
19 Jan 26

Directorate Change

Genflow Appoints a New Chairman to Accelerate Corporate and R&D Expansion
RNS 9364000 ↗
08 Jan 26

Review of 2025

2025 has been a year of focused scientific progress and continued advancement of Genflow Bioscience's mission to extend healthy lifespan through our novel longevity gene therapy platform.
RNS 9340177 ↗
16 Dec 25

Completion of Dosing Phase of Canine Gene Therapy

Genflow Completes Dosing Phase of Canine Gene Therapy Trial
RNS 9298702 ↗
11 Dec 25

Genflow to Attend Healthcare Conference

Genflow Biosciences Plc (LSE:GENF) (OTCQB:GENFF) ("Genflow" or "the Company"), a leading European-based biotechnology company focusing on longevity, announces that it will attend the 44th Annual J.P.
RNS 9289277 ↗
31 Oct 25

Total Voting Rights
RNS 9204975 ↗
24 Oct 25

Holding(s) in Company
RNS 9191415 ↗
22 Oct 25

Second European Patent Application

Publication of Second European Patent Application - SIRT6 Variant for NASH
RNS 9185831 ↗
20 Oct 25

Recognition of Patentability of Claims

European Patent Office 2025 Recognizes the Patentability of Claims of SIRT 6 Variant Patent
RNS 9180359 ↗
10 Oct 25

Update on Animal Health Program

LONDON, UK-Genflow Biosciences Plc (LSE:GENF)(OTCQB:GENFF) ("Genflow" or "the Company"), the only publicly listed longevity company in Europe, is pleased to provide an update on its Dog Aging (GF-1004) study, a proof-of-concept clinical trial evaluating...
RNS 9162270 ↗
09 Oct 25

Update, Equity Issue and PDMR Notification Director buys

Termination of Initial Transaction, Subscription of New Ordinary Shares, Warrant Issue and PDMR Dealings
RNS 9159597 ↗

Source: Investegate RNS archive. Quotes are short extracts. Not investment advice.